Patient disposition and characteristics
Tumors
TUMORS, DISEASE, ONCOLOGY
Between November 20, 2014 and September 6, 2017, 62 patients were randomly assigned to receive treatment with CIK-SOX (n=31) or SOX alone (n=31). Three patients in the SOX group withdrew their informed consent and did not start the study treatment. Thus, SS and FAS included 31 patients in the CIK-SOX group and 28 patients in the SOX group (A flow diagram for the study. 62 patients were randomly assigned to receive autologous CIK cells in combination with SOX or SOX alone. 3 patients in SOX group withdrew their informed consent and did not start the study treatment. 31 patients in CIK-SOX group and 28 patients in SOX group were evaluated for safety and efficacy. 29 patients in the CIK-SOX group and 25 patients in the SOX group had measurable lesions, and assessed ORR and DCR. CIK, cytokine-induced killer; SOX, S-1 + oxaliplatin; CIK-SOX, autologous CIK cells in combination with SOX; RECIST, Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; DCR, disease control rate.Baseline characteristics.*The initial diagnosis was unresectable. SOX, S-1+oxaliplatin; CIK-SOX, CIK cells in combination with SOX; ECOG, Eastern Oncology Collaboration Group; PS, performance status.